Latest Capital Raising News

Blue Energy Limited has successfully raised $3.2 million through a two-tranche placement, complemented by a proposed $250,000 share purchase plan, to fund drilling and pipeline development in Queensland’s North Bowen Basin.

Adslot Ltd reported a 34% drop in revenue to $5.77 million for FY25 but significantly reduced its net loss by 65% to $3.7 million, driven by cost cuts and strategic partnerships. The company is focused on growing its Trading Technology segment despite ongoing market challenges.

Staude Capital Global Value Fund Limited reported a 21% increase in net profit after tax for FY2025, driven by strong portfolio returns and a successful discount capture strategy. The company also declared a fully franked final dividend of 3.3 cents per share and completed a $16.9 million wholesale placement.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

Bathurst Resources reports a dip in FY25 earnings due to lower coal prices and operational challenges but pushes forward with key development projects Buller and Tenas, targeting production growth from FY29.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

Immuron Limited reported a strong 48.6% revenue increase driven by Travelan sales in Australia and North America, yet still recorded a $5.25 million net loss for FY25. The company’s cash reserves fell sharply, prompting a post-year capital raise.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

EPX Limited reported a 17.2% increase in revenue to $15.27 million for FY2025, alongside an 18.7% rise in net loss to $5.75 million. The company expanded its energy management portfolio with the acquisition of UK-based Coda Cloud Limited and raised $5 million in equity to fuel growth.